Our research focuses on enhancing the methodology to obtain high quality prostate cancer tissue samples. It addresses challenges like genetic intratumoral heterogeneity, multifocality, and precise molecular characterization of tumor foci in prostate cancer research. Biobanking is a technology driving practice that systematically collects processes and stores biological samples.
Integrating these technologies enables the generation of extensive dataset from well characterized prostate cancer samples, fostering collaboration, improving research, reliability, and aiding in the development of personalized medicine and strategies for prostate cancer patients. Pathology faces several experimental changes including intratumoral heterogeneity, histopathological standardization, molecular data integration, lab intensive processes, climate quantitative analysis underneath for automated e-image analysis. Addressing these issues requires ongoing technological advancements, a standardization initiatives, interdisciplinary collaborations, and improved experimental and computational methods.
The protocol handles tumor sampling, efficiently and accurately. Integrates imaging and biopsy data for precise localization. Offers realtime histopathological insights, reduces costs and time, improves sample quality, and minimize all ischemia time.
This addresses critical challenges in prostate cancer histopathological research. Our protocol can transform prostate cancer research by improving tumor understanding both histopathological data, enhancing biobanking, fostering collaboration, and enabling personalized medicine. Longitudinal biobank reveals temporal changes, clarifying disease progression and treatment responses, interacting multi data, uncovers molecular nerves and novel biomarkers for prostate cancer.